COPENHAGEN, April 15 /PRNewswire/ -- Summary: Genmab has announced that HuMax-EGFr (zalutumumab) inhibits epidermal growth factor receptor signaling by locking epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth.

Genmab A/S (OMX: GEN) announced today new insights showing that HuMax-EGFr(TM) (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth.

There are many on-going themes in the large discussion of global warming and replacing fossil fuels with renewable, clean energy. One of the dominant ones is that alternative fuels such as solar are much more expensive than fossil fuels. This argument is often put forth by those entrenched in the status quo of the fossil fuel industry. The general argument is that our entire economic world will take a hit if we use solar as it is so much more expensive that oil.

There was a recent news story here at ScientificBlogging saying that it will take another ten years for solar energy to be price-competitive with fossil fuels.

PARIS, April 15 /PRNewswire/ --

(EUR millions) 2008 2007 08/07 % sales % sales % change Southern Europe 37.93 77.4 33.32 78.3 14 Other EU countries 9.38 19.1 8.07 19.0 16 Other markets 1.68 3.5 1.16 2.7 45 SLIT 40.86 83.4 34.63 81.4 18 SCIT 6.25 12.8 6.17 14.5 1 Other products 1.88 3.8 1.75 4.1 7 Q1 sales 48.99 100.0 42.55 100.0 15

Sales growth and financial position

First quarter sales continued to grow at a solid pace in all of the Company's markets and were up 15% compared to the first quarter of 2007, in respect of which particularly strong 20% growth had already been reported. Underlying trends were confirmed: vibrant SLIT (up 18%) and stable SCIT.

BUFFALO GROVE, Illinois, April 15 /PRNewswire/ --

Eagle Test Systems, Inc. (Nasdaq: EGLT) will release its second quarter fiscal year 2008 earnings results on Tuesday April 29, 2008, following the close of the financial markets. The company will hold a conference call on the same day at 5:00 p.m. Central time/6:00 p.m. Eastern time.

In addition to quarterly results, the conference call may include comments on developments during the quarter. Len Foxman, Chief Executive Officer and President, and Steve Hawrysz, Chief Financial Officer, will host the session.

GLASGOW, Scotland, April 15 /PRNewswire/ -- Excalibur, the new international investment house launched by Sir Christopher Evans, today (Tuesday) welcomed the sale of PIramed to Roche.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 )

The sale of PIramed to Roche for $185 million means a 'very substantial cash return' to investors in Merlin III, the investment fund created by Sir Christopher five years ago.

Merlin Biosciences were co-founding investors in PIramed at the outset in 2003 with JP Morgan. Merlin, with the founders of the company, also selected the CEO, the management team, built the board of directors and continued to provide ongoing funding and strategic advice to the company.

Female fruit flies sometimes choose males who are aggresive, sometimes choose males who do not fight at all, and sometimes choose males for no reason science can explain, write a team of biologists, and the findings help explain the large variation in aggressiveness in most species, including humans.

So females are unpredictable, which means the fittest males don’t always get the girl. This explains why males don't evolve towards super-aggressiveness.

“If aggression makes you more likely to father children, all males should be selected to be very aggressive. Male fruit flies (like humans and other animals) show a lot of genetic variation in aggression, and we wanted to find out why,” explained study leader Brad Foley, a post-doctoral researcher at USC.

SAN JOSE, California, April 15 /PRNewswire/ --

- Company announces strategy for product renaming, outlines plan for new solutions in key device categories and unveils first developer certification.

SAN JOSE, California, April 15 /PRNewswire/ --

- New programme features developer tools, embedded operating systems, and board packages for hobbyist developers and academic community.

At the Embedded Systems Conference today, Microsoft Corp rolled out the full details about its SPARK Your Imagination community-focused programme, a joint agreement between Microsoft and select hardware vendors to bring a complete offering of hardware and software to nonprofessional developers through a simple and affordable engagement model. The programme offerings have an estimated retail value of US$1,300 and will be available immediately worldwide at prices ranging from US$250 to US$350.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

CALGARY, Canada, April 15 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY) announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Radiation in Combination with Reolysin for Pediatric Sarcomas" was presented today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held in San Diego, California from April 12-16, 2008.

"The combination of REOLYSIN(R) with radiation is certainly favourable," said Dr. Kolb. "Statistically significant improvements in event-free survival are seen in mice treated with the combination when compared to either therapy alone."